Niesvizky R

Idioma: Español
Referencias bibliográficas: 15
Paginas: 153-155
Archivo PDF: 312.02 Kb.

FRAGMENTO

El carfilzomib (Kyprolis, Onyx) es un inhibidor de proteosoma de segunda generación, derivado de la epoximicina, de la clase de las epoxicetonas; está aprobado por la Dirección de Alimentos y Fármacos para su administración en el tratamiento del mieloma múltiple resistente o en recaída.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Meng L, Mohan R, Kwok HB, et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. PNAS 1999;96:10403-10408.

2. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67:6383-6391.

3. Elofsson M, Splittgerber U, Myung J, et al. Towards subunitspecific proteasome inhibitors: synthesis and evaluation of peptide alpha’,beta’-epoxyketones. Chem Biol 1999;6:811- 822.

4. O’Connor OA, Stewart AK, Vallone M, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009;15;7085.

5. Alsina M1, Trudel S, Furman RR, et al. A phase I singleagent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res 2012;18:4830-4840.

6. Jakubowiak AJ. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview. Cancer Treat Rev 2014;40:781-790.

7. Siegel DS1, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171- 003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012;120:2817-2825.

8. Niesvizky R, Martin TG 3rd, Bensinger WI, et al. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res 2013;19:2248- 2256.

9. Wang M, Martin T, Bensinger W, et al. Phase 2 doseexpansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 2013;122:3122-3128.

10. Siegel D1, Martin T, Niesvizky R, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013;98:1753-1761.

11. Lee SJ, Arastu-Kapur S, Kellerman L, et al. Potent inhibition of select proteasome subunits by carfilzomib in multiple myeloma and solid tumor patients is associated with patient response. Haematologica 2012;97:344.

12. Palumbo A1, Bringhen S, Larocca A, et al. Bortezomibmelphalan- prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol 2014;32:634-640.

13. Reeder CB, Reece DE, Kukreti V, et al. Once-versus twiceweekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 2010;115:3416-3417.

14. Berenson JR, Klein L, Rifkin RM, et al. A phase 1, doseescalation study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma. ASH 2013;1934.

15. Ruiz-Delgado GJ, Vallejo-Villalobos MF, Galindo Becerra S, Ruiz-Argüelles GJ. Low-dose carfilzomib induced a dramatic response of the symptoms and paraproteinemia in a heavily pre-treated multiple myeloma patient refractory to lenalidomidebortezomib-dexametasone. Rev Hematol Mex 2014;15:137-141.